BIOMARKER OF LIVER CANCER AND USES THEREOF
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 22, 2016
app pub date -
Jul 29, 2015
filing date -
Jul 29, 2015
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to uses of nucleolin as a biomarker of liver cancer, comprising predicting, detecting, diagnosing or monitoring liver cancer, high risk of liver cancer, or high risk of vascular invasion of hepatoma cells in a subject, and assessing prognosis of a subject suffered from liver cancer by nucleolin expression level. The biomarkers for determining expression level of nucleolin, kit for determining liver cancer, high risk of liver cancer, or high risk of vascular invasion of hepatoma cells in a subject by expression level of nucleolin, and use of small interfering RNA or antibody specific for recognizing nucleolin in manufacturing medicine for treating liver cancer are also included in the present invention.
First Claim
Other Claims data not available